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ABSTRACT
The development of antibiotic resistance by bacteria is an evolutionary inevitability, a convincing
demonstration of their ability to adapt to adverse environmental conditions. Since the emergence of
penicillinase-producing Staphylococcus aureus in the 1940s, staphylococci, enterococci and streptococci
have proved themselves adept at developing or acquiring mechanisms that confer resistance to all
clinically available antibacterial classes. The increasing problems of methicillin-resistant S. aureus and
coagulase-negative staphylococci (MRSA and MRCoNS), glycopeptide-resistant enterococci and
penicillin-resistant pneumococci in the 1980s, and recognition of glycopeptide-intermediate S. aureus
in the 1990s and, most recently, of fully vancomycin-resistant isolates of S. aureus have emphasised our
need for new anti-Gram-positive agents. Antibiotic resistance is one of the major public health concerns
for the beginning of the 21st century. The pharmaceutical industry has responded with the development
of oxazolidinones, lipopeptides, injectable streptogramins, ketolides, glycylcyclines, second-generation
glycopeptides and novel ﬂuoroquinolones. However, clinical use of these novel agents will cause new
selective pressures and will continue to drive the development of resistance. This review describes the
various antibiotic resistance mechanisms identiﬁed in isolates of staphylococci, enterococci and
streptococci, including mechanisms of resistance to recently introduced anti-Gram-positive agents.
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INTRODUCTION
We have been using antibiotics for <70 years but,
despite our proven technological innovation, we
are constantly being challenged by the ready
adaptability of the bacterial pathogens that we
naively sought to conquer and eradicate. This
‘arms race’ has resulted in bacteria that are
resistant to all antibacterial classes. Antibiotic
resistance remains, more than ever, a key issue for
medical microbiology.
Yet, despite frequent banner headlines in the
mass media, there are relatively few ‘superbugs’,
if one deﬁnes these as bacterial pathogens
resistant to all clinically available agents. From a
clinical perspective, the bacteria justifying the
term most fully are multi-resistant Gram-negative
species (Pseudomonas spp., Acinetobacter spp. and
members of the Enterobacteriaceae), which are
isolated with increasing frequency both in hospi-
tals and, even more worryingly in some instances,
in the community; there is a dearth of novel
agents active against such resistant isolates [1,2].
However, the epithet is more often applied to
resistant strains of Gram-positive species, especi-
ally to methicillin-resistant Staphylococcus aureus
(MRSA) and to glycopeptide- or vancomycin-
resistant enterococci (GRE or VRE). The pharma-
ceutical industry has provided a number of
recently licensed products that are active against
the vast majority of such strains, and still further
anti-Gram-positive agents are in development [3].
However, the spectre of resistance is never far
from the horizon. There have been reports of
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resistance to novel agents, including to those
licensed for clinical use since the beginning of the
21st century.
This article reviews the myriad mechanisms of
resistance to diverse antibiotic classes that have
been identiﬁed in resistant Gram-positive bac-
teria. A summary of these mechanisms is provi-
ded in Table 1.
b -LACTAM RESISTANCE
The b-lactams are the most widely used antibac-
terial class. Since the introduction of penicillin in
the 1940s, the class has been developed and
expanded to provide a continuing ﬂow of agents
with enhanced activity against bacteria resistant
to preceding members.
Methicillin was introduced in the early 1960s to
combat hospital strains of penicillinase-producing
S. aureus, it being resistant to hydrolysis by these
enzymes. However, resistance to methicillin was
noted shortly thereafter [4]. MRSA and methicil-
lin-resistant coagulase-negative staphylococci
(MRCoNS) are all too familiar in today’s hospitals
[5]. In England and Wales, MRSA accounts for
c. 40% of S. aureus from bacteraemias, and >70%
of CoNS isolates from bacteraemias are methicil-
lin-resistant [6]. The majority of UK MRSA iso-
lates belong to two epidemic strains, designated
EMRSA-15 and EMRSA-16 [7]. Successful clones
of MRSA have been documented worldwide, and
molecular epidemiology is now being used to
monitor their spread [8,9].
Methicillin resistance arises following the
acquisition of novel DNA, which results in pro-
duction of a new penicillin-binding protein (PBP),
known as PBP2¢ or PBP2a, which has low binding
afﬁnity for methicillin and other currently avail-
able b-lactams (several novel anti-MRSA cephalo-
sporins are being developed [3]). PBP2¢ is the
product of the c. 2 kb mecA gene, which is part of
a much larger mobile genetic element, the sta-
phylococcal chromosomal cassette mec (SCCmec).
At least ﬁve different SCCmec types have been
described, which vary in size from c. 20 kb (type
IV) to c. 70 kb (type III) [10–13]. In addition to
mecA, these complex genetic elements may also
contain integrated plasmids and transposons
conferring resistance to other antibiotic classes.
Analysis of SCCmec and other staphylococcal
chromosomal cassettes is providing new insights
into the evolution and population biology of
MRSA strains [9,11,14–17]. The origin of mecA
remains uncertain, although a homologue has
been identiﬁed in Staphylococcus sciuri [18].
Althoughpenicillinase production is common in
S. aureus, it is very rare in enterococci [19–22], and
has not been reported in streptococci. Enterococci
are intrinsically resistant to marketed cephalospo-
rins because of the presence of PBP with low
afﬁnities for these agents [23]. Also, they are often
tolerant of the bactericidal action of penicillins,
although this may be an acquired characteristic
[24]. Non-penicillinase-mediated resistance to
ampicillin and penicillin is particularly associated
with isolates of Enterococcus faecium (MIC, >8 mg/
L) and also results from the presence of a low-
afﬁnity PBP, PBP5 [25]. Mutations affecting chro-
mosomal genes, such as those encoding PBP, are
not usually considered to be transferable, but
mobilisation of pbp5 by an adjacent copy of
transposon Tn5382, which encodes VanB glyco-
peptide resistance (see below), has been observed
from some E. faecium strains in the USA [26].
The rule that bacteria always develop resistance
to antibiotics holds for most ‘bug/drug’ combi-
nations. It is equally true that there is an exception
to every biological rule. Despite over 60 years of
penicillin use, no mechanism of penicillin resist-
ance has been documented in b-haemolytic strep-
tococci of Lanceﬁeld groups A, C or G. The reason
for this absence is unknown, although isolates
suspected to show resistance have been alluded to
on occasion [27]. Clinical isolates of group B
streptococci also remain susceptible to penicillin
[6,28], although there is a report of resistance in
Streptococcus agalactiae from dairy cows [29].
Penicillin resistance does occur in viridans strep-
tococci and in Streptococcus pneumoniae. As with
enterococci, the mechanism involves PBPs with
reduced binding afﬁnities, but in streptococci
these are the products of mosaic genes that have
arisen via inter-species transformation and
recombination events [30–32]. Penicillin resistance
develops in a step-wise manner with the level of
resistance in a particular strain reﬂecting the
number of PBPs affected by the mosaicism. Thus,
for example, pneumococci with intermediate
penicillin resistance (MIC, 0.1–1 mg/L) typically
have fewer mosaic PBP species than isolates with
full resistance (MIC, ‡2 mg/L). Alterations to
PBPs may also cause unusual resistance pheno-
types, such as isolates of pneumococci that exhibit
oxacillin resistance while remaining susceptible to
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penicillin [33], have higher MICs of amoxicillin
than of penicillin [34], and have resistance to
cefotaxime [35,36].
The prevalence of penicillin non-susceptible
pneumococci (isolates with intermediate or full
resistance) varies markedly between countries.
The worldwide prevalence of fully penicillin-
resistant pneumococci, estimated from over 8000
isolates from community-acquired respiratory
tract infections in 26 countries, was 18.2% in
1998–2000 [37]. A rate of 35.4% (14.2% interme-
diate, 21.4% full resistance) among 10,000 com-
munity-acquired pneumonia isolates collected in
2001–2002 has recently been reported in the USA
[38]. Among invasive isolates in the UK, data
from the European Antimicrobial Resistance Sur-
veillance System (EARSS) project indicate a
decrease in penicillin non-susceptibility from 4%
in 2000 to 0.5% in 2004 (http://www.earss.
rivm.nl; accessed 23/09/2004). In another survey,
intermediate penicillin resistance was noted in
9% of pneumococci from bacteraemia in the UK
and Republic of Ireland, with no isolates showing
full resistance [6].
GLYCOPEPTIDE RESISTANCE
Transferable glycopeptide resistance was ﬁrst
reported in 1987 and 1988 with the recognition
of VanA enterococci [39–41]. Since that time, six
different resistance types have been deﬁned in
enterococci; ﬁve are acquired (VanA, VanB,
VanD, VanE and VanG), while the sixth, VanC,
is intrinsic to Enterococcus gallinarum and Entero-
coccus casseliﬂavus/Enterococcus ﬂavescens. GRE
of all six types produce altered peptidoglycan
pentapeptide precursors that terminate not in
the typical D-alanyl-D-alanine, but in either of
D-alanyl-D-lactate (VanA, VanB and VanD) or
D-alanyl-D-serine (VanC, VanE, VanG) [42,43],
which results in a much-decreased binding afﬁn-
ity for glycopeptides.
These substantial changes in peptidoglycan
composition do not result from acquisition of a
single gene; each resistance type is associated
with a complex gene cluster [42]. The prototype
VanA resistance cluster is found on transposon
Tn1546 [44], which carries nine genes, variously
responsible for transposition (orf1 and orf2),
regulation and expression of resistance (vanR-
SHAX) and accessory functions (vanY and vanZ).
Similar gene clusters are found in the otherFu
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resistance types [26,42,45–53]. Phenotypically,
VanA resistance is associated with high-level
resistance to vancomycin (typical MIC,
>128 mg/L) and, in the vast majority of strains,
with cross-resistance to teicoplanin (MIC, ‡8 mg/
L); some isolates with mutations in the vanS
regulatory gene appear susceptible (or have only
borderline resistance) to teicoplanin [54,55]. Other
glycopeptide resistance types confer vancomycin
resistance (although this may not be obvious
according to all methods of susceptibility testing
used in clinical laboratories), but usually spare
teicoplanin, at least in vitro. VanA enterococci are
also resistant to dalbavancin, a phase III devel-
opmental glycopeptide (MIC90, 32 mg/L vs.
£0.5 mg/L for other enterococci) [3,56]. GRE of
all types usually remain susceptible to the novel
glycopeptide, oritavancin, which has an evolved
mechanism of action (in addition to binding D-ala-
D-ala it also seems to inhibit transglycosylases)
[57,58], and which is also in phase III clinical trials
[3], although VanA and VanB enterococci can
acquire moderate levels of resistance to this agent
(MIC, £16 mg/L) in a single step [59].
There is homology between genes conferring
acquired glycopeptide resistance in enterococci
and the intrinsic resistance genes of glycopeptide-
producing species and also, to some extent, in their
organisation within clusters [60–63]. However,
although it is likely that the producers were the
ancestral source of resistance genes, the percentage
G + C content of their genes differs markedly from
that of enterococcal van genes, which argues
against recent, direct escape and transfer events.
In Europe, selective pressure for the emergence
and dissemination of GRE (particularly VanA
strains) in food production animals was exerted
by use of the glycopeptide avoparcin as a growth
promoter. The contribution made by this non-
human reservoir of van resistance genes to the
problem of GRE in hospitals is still hotly debated
(as are similar issues for other ‘bug/drug’ combi-
nations) [64,65]. The use of avoparcin was banned
throughout the European Union in 1997 [66].
Currently, the prevalence of GRE in the UK is
20% in E. faecium and 3% in E. faecalis among
enterococci isolated from bacteraemias [6]. Similar
rates of glycopeptide resistance occur in some
parts of Europe, including Greece, Ireland and
Italy, but elsewhere in Europe, prevalence rates in
E. faecium are typically <10% (EARSS project data,
http://www.earss.rivm.nl; accessed 23/09/2004).
Glycopeptides retain a key role in the treatment
of serious infections caused by MRSA or
MRCoNS. Detection and spread of glycopeptide
resistance in enterococci therefore prompted con-
cerns that this resistance would ‘escape’ into
staphylococci. This event was not detected until
2002, when two epidemiologically unrelated iso-
lates of MRSA with the vanA gene cluster were
identiﬁed in the USA [67–69]; a third unrelated
vanA vancomycin-resistant S. aureus (VRSA) was
reported recently, again from the USA [70].
Vancomycin MICs for these three isolates ranged
from 32 to 1024 mg/L; all remained susceptible to
linezolid, quinupristin–dalfopristin, and to older
antibacterial agents, including rifampicin (two of
three isolates), minocycline, chloramphenicol and
co-trimoxazole.
Predating VRSA, but also causing public health
concern, vancomycin- or glycopeptide-intermedi-
ate S. aureus (VISA or GISA) were ﬁrst detected in
Japan in 1997 [71,72], and subsequently in other
countries [73–77]. These isolates display low-level
vancomycin resistance (typical MIC 8–16 mg/L;
categorised as ‘intermediate’ by the interpretative
criteria of the National Committee for Clinical
Laboratory Standards, hence the acronym), and
decreased susceptibility to teicoplanin. Yet other
S. aureus isolates may contain vancomycin-resist-
ant sub-populations (so-called hetero-VISA/het-
ero-GISA) [78]. Analysis of data from the EARSS
project (http://www.earss.rivm.nl; accessed 23/
09/2004) revealed only two S. aureus isolates (of c.
65 000 isolates collected from 1999–2004 in 26
European countries) that showed decreased sus-
ceptibility to vancomycin (the level of resistance
was not speciﬁed). Although this low prevalence
conﬁrms a previous report from the UK [79], the
potential for poor detection of VISA/GISA in
clinical laboratories [73] must be considered in
international surveys.
Isolates of CoNS, particularly Staphylococcus
epidermidis and Staphylococcus haemolyticus [80],
commonly show substantial resistance to teicopl-
anin (typical MIC, £64 mg/L) while remaining
susceptible to vancomycin (MIC, £4 mg/L). The
prevalence of this phenotype was estimated at
35% of CoNS from bacteraemia in the UK and
Republic of Ireland [6]. Teicoplanin resistance, but
vancomycin susceptibility, has also been reported
rarely in S. aureus [80]. The prevalence of vanco-
mycin-resistant CoNS in Europe has been estima-
ted in several multicentre studies to be £0.5% [81].
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The mechanism(s) of resistance in GISA, tei-
coplanin-resistant S. aureus and glycopeptide-
resistant CoNS are unrelated to those of GRE or
intrinsically glycopeptide-resistant Gram-positive
species. The precise genetic basis for resistance
remains elusive, but the GISA phenotype includes
thickened cell walls and over-production of
D-alanyl-D-alanine-containing peptidoglycan pre-
cursors [78,82–84]. Some GISA isolates have dis-
rupted agr function (a virulence regulatory locus
[85]), and an agr-null mutant gained hetero-
resistance to vancomycin and was tolerant of its
bactericidal effects [86]. Mutations that inactivate
tcaA, which encodes a putative trans-membrane
protein, have also been associated with the GISA
phenotype, but the mechanism has not been
deﬁned [87].
Vancomycin resistance is very uncommon
among streptococci, but has been reported in an
isolate of Streptococcus bovis from a human stool
swab [88], and in isolates of Streptococcus gallolyt-
icus [89,90] and Streptococcus lutetiensis [90] from
faecal samples of veal calves. In these rare cases,
resistance resulted from acquisition of gene clus-
ters mediating the enterococcal VanB [88–90] or
VanA [89] resistance mechanisms. Glycopeptide
resistance has never been reported in S. pneumo-
niae, although tolerance to the bactericidal activity
usually shown by vancomycin against this species
has been documented [91,92].
AMINOGLYCOSIDE RESISTANCE
Although streptococci and enterococci are insus-
ceptible to aminoglycosides (typical gentamicin
MIC, 8–64 mg/L) owing to poor transport across
the cytoplasmic membrane, a synergistic combina-
tion of a cell wall-active agent (penicillin or glyco-
peptide) with an aminoglycoside remains the
treatment of choice for endocarditis caused by
enterococci and viridans streptococci [93–95]. In-
deed, for enterococci this is the only currently
licensed therapeutic option that consistently shows
bactericidal activity against susceptible isolates.
Most monotherapeutic agents will not reliably kill
the majority of enterococci, although the lipopep-
tide, daptomycin, which is licensed in the USA
(albeit not for use for the treatment of endocarditis),
and the second-generation glycopeptide, oritavan-
cin (in phase III trials), are both rapidly bactericidal
against many strains, including GRE (and also
against MRSA, GISA and VRSA) [3]. Enterococci
that present with high-level aminoglycoside resist-
ance (gentamicin MIC, >512 mg/L; streptomycin
MIC, >2000 mg/L) therefore cause therapeutic
problems as the synergistic activity of the combi-
nation is abolished.
Although ribosomal mutation can result in
such high levels of aminoglycoside resistance
in vitro, especially to streptomycin [96], most
resistance in the clinic is mediated by aminogly-
coside modifying enzymes (AMEs). AMEs fall
into three classes depending upon their bio-
chemical effect on the aminoglycoside substrates,
namely acetyltransferases (AAC), phosphotransf-
erases (APH) and nucleotidyltransferases (ANT).
Many different AMEs have been reported in
staphylococci, enterococci and streptococci, and
detection of identical genes in different genera
provides evidence for the intergeneric spread of
resistance genes.
High-level gentamicin resistance in enterococci
has a prevalence in the UK of 25–50% among
isolates from bacteraemias [6]. The most common
mechanism underlying this phenotype is produc-
tion of a bifunctional AME, AAC(6¢)-APH(2¢¢).
The same enzyme is also found in gentamicin-
resistant staphylococci, and has also been reported
in occasional isolates of high-level gentamicin-
resistant group B [97,98], group G [99] and
viridans streptococci [100], and in Aerococcus sp.
[101]. It confers resistance to all aminoglycosides
available in Europe, except streptomycin. How-
ever, arbekacin, which is available in Japan, is a
relatively poor substrate for AAC(6¢)-APH(2¢¢),
and many gentamicin-resistant enterococci and
staphylococci remain susceptible to it [102–105].
Although less prevalent than the AAC(6¢)-
APH(2¢¢) bifunctional enzyme, acquired gentam-
icin resistance in enterococci (albeit not always at
high-level) may also be conferred by APHs
encoded by aph(2¢¢)-Ib [106,107], aph(2¢¢)-Ic
[108,109], and aph(2¢¢)-Id [110]. Arbekacin has
been reported to retain useful activity against
enterococci producing APH(2¢¢)-Id [111].
High-level kanamycin resistance with amikacin
resistance (the latter not always at high level) is
commonly encoded by aph(3¢)-III [112–114], while
resistance to these combined with resistance to
tobramycin (but not to gentamicin) implies pres-
ence of ant(4¢)-I [114,115]; both mechanisms have
been described in enterococci and staphylococci;
aph(3¢)-III also occurs in pneumococci [116–118].
High-level streptomycin resistance is most
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commonly encoded by ant(6)-I, or by the ANT
encoded by ant(9)-I and ant(3¢¢)-I [114,119]. An
ANT(3¢¢) activity has also been reported in iso-
lates of Streptococcus mitis with high-level strep-
tomycin and kanamycin resistance [120]. Linkage
of ant(6)-I (also known as aadE) and aph(3¢)-III
(aphA-3) has been demonstrated in all three
genera, occasionally also including linkage to
aac(6¢)-aph(2¢¢) [121,122].
RESISTANCE TO MACROLIDES,
LINCOSAMIDES, STREPTOGRAMIN-
B AGENTS AND KETOLIDES
The numerous mechanisms responsible for
resistance to macrolides (M), lincosamides (L)
and streptogramin B agents (SB) have been the
subject of recent review and nomenclature chan-
ges [123].
Cross-resistance to these three chemically
diverse classes of compounds (the MLSB pheno-
type) is conferred by a large number of 23S rRNA
methylases, encoded by erm genes. These
enzymes either mono- or dimethylate nucleotide
A2058 [123], which is critical for interactions
between the 23S rRNA and MLSB agents [124].
The erm determinants may be expressed inducibly
or constitutively. Macrolides (14 and 15-mem-
bered) are good inducers of resistance, but lin-
cosamides vary in their ability to induce, being
better in streptococci [123] than in staphylococci.
Thus, staphylococci with inducible erm genes
usually appear macrolide-resistant, but clindamy-
cin-susceptible in vitro. Clindamycin should be
avoided when considering treatment of infections
caused by macrolide-resistant staphylococci
because of the risk of selecting mutants with
constitutive erm expression; these are resistant to
all MLSB agents in vitro. Theoretically, clindamy-
cin remains an option if the macrolide resistance
was efﬂux-mediated (see below), but distinguish-
ing between Erm-mediated resistance and other
macrolide resistance mechanisms is often not
undertaken in clinical laboratories.
Ketolides, such as telithromycin, are poor
inducers of erm genes and are active against
many macrolide-resistant streptococci [3]. How-
ever, the extent to which they retain activity
against bacteria that express erm genes constitu-
tively varies [125]. This depends ﬁrst on the
particular erm determinant present (those
enzymes that monomethylate A2058 result in
only moderate increases in MICs of telithromycin,
whereas those that dimethylate A2058 may confer
high-level telithromycin resistance) and, sec-
ondly, on the efﬁciency of dimethylation in the
particular species. Thus, constitutive Erm(B)-pro-
ducing Streptococcus pyogenes are resistant to
telithromycin, whereas constitutive Erm(B)-pro-
ducing S. pneumoniae remain susceptible [126]
most probably because the dimethylation step is
more efﬁcient in S. pyogenes [125].
Efﬂux pumps belonging to the major facilitator
family [123,127,128] represent the other common
mechanism of macrolide resistance; they confer
resistance to macrolides only (the M phenotype)
[123,129]. The mef genes that encode these pumps
are mobile and have been found in streptococci,
enterococci and several other genera [130]. mef(A)
and mef(E) were originally detected in S. pyogenes
and S. pneumoniae, respectively [123], although
their distribution is not species-speciﬁc [131].
These genes, which share 90% DNA identity,
have been considered to represent a single class,
designated mef(A) [123], although differences in
the genetic elements carrying them have led
others to maintain the distinction [131].
The erm and mef genes are the most prevalent
causes of macrolide resistance in Gram-positive
cocci (see below). However, other mechanisms
may be present: efﬂux pumps belonging to the
ATP-binding transporter family [127,128] confer
an MSB phenotype, and are encoded by msr(A)
alleles [which include the allele formerly called
msr(B)] in staphylococci [123], and by msr(C) in
E. faecium [132,133]; mutations in 23S rRNA or in
ribosomal proteins L4/L22 have been reported
in pneumococci [134–141], S. pyogenes [141,142],
and S. aureus [143]; a novel efﬂux pump, encoded
by mre(A), has been reported in S. agalactiae [144];
and macrolides may be inactivated in staphylo-
cocci that produce the Mph(C) phosphotransf-
erase [145]. Although this latter enzyme does not
confer cross-resistance to L or SB agents, the
mph(C) gene was found on a plasmid that also
carried msr(A) and erm(Y) [145].
Speciﬁc resistance only to SB agents in staphy-
lococci (and rare enterococci) is conferred by the
Vgb(A) and Vgb(B) lyases (see below) [146–149].
Speciﬁc resistance to lincosamides is conferred by
ANT, encoded by lnu(A) alleles in staphylococci
[formerly lin(A), lin(A¢) and related genes]
[123,150,151], and by lnu(B) [formerly lin(B)] in
enterococci [123,152].
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Efﬂux-mediated macrolide resistance is usually
associated with lower MICs than Erm-mediated
resistance. For this reason, macrolide MIC distri-
butions often appear trimodal for bacteria in
which both mechanisms occur, with peaks repre-
senting susceptible (erythromycin MIC, £0.5 mg/
L) ‘efﬂux-resistant’ (typical erythromycin MIC,
8–16 mg/L) and ‘Erm-resistant’ populations (typ-
ical erythromycin MIC, ‡256 mg/L). This is illus-
trated, for example, by a-, b- and non-haemolytic
streptococci from UK bacteraemias [6], and by
pneumococci from PROTEKT US [38].
The prevalence of macrolide resistance among
pneumococci exceeds rates of penicillin resist-
ance. In the PROTEKT US survey, 28% of
c. 10 000 isolates of S. pneumoniae collected in
2001–2002 were resistant to erythromycin (MIC,
‡1 mg/L), and <1% showed reduced suscept-
ibility to the ketolide telithromycin; 70% of
macrolide-resistant isolates were susceptible to
clindamycin [38]. The mechanisms detected were:
mef(A) only, 68.7%; erm(B) only, 16.8%;
mef(A) + erm(B), 12.2%; erm(A), 0.2%; and
unknown, 2% [153]. The worldwide prevalence
of macrolide resistance in pneumococci, estima-
ted from isolates collected 1998–2000, was 24.6%
[37]. In the UK, 17% of pneumococci from
bacteraemias were resistant to erythromycin [6],
as were 10% of isolates from community-ac-
quired respiratory infections [154].
Erythromycin resistance was found in 5.7% of
S. pyogenes isolates from PROTEKT US [38], and
in 10% of b-haemolytic streptococci (of groups A,
B, C and G) from UK bacteraemias [6]. In the UK
survey, 7% of b-haemolytic streptococci showed
low-level (probable Mef-mediated) macrolide
resistance; the remaining macrolide-resistant iso-
lates showed high-level (probable Erm-mediated)
resistance [6]. Similarly, 24% of a- and non-
haemolytic streptococci from UK bacteraemias
were resistant to erythromycin; 17% showed low-
level (probable Mef-mediated) resistance; and 7%
isolates showed high-level (probable Erm-medi-
ated) resistance [6].
RESISTANCE TO STREPTOGRAMIN
COMBINATIONS
A pristinamycin combination has been available
as an anti-staphylococcal agent for many years in
some European countries, for example, France
[155], but quinupristin/dalfopristin, which was
licensed in the late 1990s, represented the ﬁrst
water-soluble streptogramin combination devel-
oped for injection. Quinupristin/dalfopristin con-
sists of a synergistic mixture of a streptogramin A
(SA, dalfopristin) and a streptogramin B (SB,
quinupristin). These structurally distinct mole-
cules act on different sites of the 50S ribosomal
sub-unit and, given together, are bactericidal
against many Gram-positive bacteria [156]. The
combination is active in vitro against the
vast majority of staphylococci and against many
E. faecium, including glycopeptide-resistant
strains. However, it has no activity against most
E. faecalis strains, because of its apparent efﬂux via
the Lsa pump, which appears to be intrinsic to the
species [157–159], and its activity against other
enterococcal species may be inferior to that
against E. faecium [160].
Resistance to streptogramin combinations
requires resistance speciﬁcally to the SA compo-
nent, but is augmented by the presence of mech-
anisms conferring SB resistance [161]. SA resistance
can be mediated by several mechanisms: speciﬁc
acetyl transferases encoded by vat(A), vat(B) and
vat(C) have been characterised in staphylococci
[147,162,163], and by vat(D) and vat(E) (formerly
satA and satG) in E. faecium [164,165]; also, SA
efﬂux pumps encoded by vga(A) and vga(B) have
been identiﬁed in staphylococci [166,167]. Cross-
resistance encompassing SB compounds is com-
monly mediated by erm determinants (see above),
but speciﬁc resistance to SB agents is mediated by
lyases, which inactivate the compounds and
which are encoded by vgb(A) and vgb(B) [146–
148]. Although these genes occur mainly in
staphylococci, vgb(A) has been identiﬁed in occa-
sional isolates of enterococci [149]. The vat(A–E)
genes are often plasmid-mediated in staphylo-
cocci and E. faecium, which permits ready transfer
between strains. Genetic linkage of multiple strep-
togramin resistance mechanisms on individual
plasmids has been reported [147,168,169], as has
linkage to genes conferring resistance to other
antimicrobial classes [170–173]. In addition to
acquired resistance mechanisms, low-level resist-
ance to quinupristin/dalfopristin (MIC, 4 mg/L)
arising from mutations in rplV, which encodes
ribosomal protein L22, has been reported in a
clinical isolate of S. aureus [143] and in two clinical
isolates of S. pneumoniae [136].
There is concern that dissemination of vat(D)
and vat(E) in E. faecium has been selected by use of
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virginiamycin (another streptogramin combina-
tion) as a growth promoter in food production
animals. These genes are found relatively readily
in enterococci isolated from treated animals and
retail meat [174–180], but have also been recov-
ered from isolates from human clinical specimens
or faeces, in some instances prior to licensing of
quinupristin/dalfopristin [173,181,182], which
provides circumstantial evidence for spread from
a pre-existing reservoir of resistance. However,
clinical isolates of E. faecium resistant to strep-
togramin combinations remain rare, which prob-
ably reﬂects low usage of quinupristin/
dalfopristin. Low-level quinupristin/dalfopristin
resistance (MIC 4–8 mg/L) may also be observed
in clinical isolates of E. faecium that lack deﬁned
resistance determinants.
FLUOROQUINOLONE RESISTANCE
The ﬂuoroquinolones target DNA gyrase (topo-
isomerase II) and topoisomerase IV, which are
essential for the DNA supercoiling of bacterial
DNA and any process that requires it (e.g., DNA
replication, transcription, etc.). Resistance to
ﬂuoroquinolones, which are synthetic, arises via
mutational target modiﬁcation or efﬂux; drug
inactivation has not been reported in bacteria.
Earlier analogues, such as ciproﬂoxacin, tend to
be affected more than newer generation ﬂuoro-
quinolones; as with many other antibiotic classes,
the pharmaceutical industry has provided a mul-
titude of novel quinolones, which extend the
spectrum of the class, particularly against Gram-
positive cocci [3,183].
In contrast with mutational resistance to many
other antibiotics, acquisition of a single target-
modifying mutation does not usually confer
signiﬁcant ﬂuoroquinolone resistance. Rather,
resistance is a cumulative process, with increasing
numbers of mutations generally correlating with
increasing MICs of ﬂuoroquinolones. Both the
DNA gyrase and topoisomerase IV targets consist
of sub-units. These are encoded by gyrA and gyrB
(for DNA gyrase), and by parC and parE (for
topoisomerase IV). Mutations that confer ﬂuoro-
quinolone resistance arise in gyrA and parC
(changes in gyrB and parE also occur, but are less
common), and are usually clustered in speciﬁc
areas of the genes, known as the quinolone
resistance determining regions. The quinolone
resistance determining regions centre around the
codons that encode residues serine-81 of GyrA
and serine-79 of ParC. The mechanisms and
epidemiology of ﬂuoroquinolone resistance in
Gram-positive cocci have been reviewed recently
[184–186]. Low-level resistance results from muta-
tions in either GyrA or ParC, whereas high-level
resistance is associated with mutations in both
proteins. The gene affected in ﬁrst-step muta-
tional events depends on the primary lethal target
of the ﬂuoroquinolone under study; some ana-
logues target GyrA preferentially, others ParC,
and yet others have ‘dual action’ [3,183]. Muta-
tional resistance to ﬂuoroquinolones has been
reported extensively in staphylococci and pneu-
mococci (for reviews, see [185,186]). It also occurs
in enterococci [187–192], and has been reported in
occasional isolates of S. pyogenes [193–195].
Efﬂux-mediated resistance involves multi-drug
efﬂux pumps (MDRs) belonging to the major
facilitator family [123,127,128] rather than ﬂuoro-
quinolone-speciﬁc channels, so other antibiotic
classes tend also to be affected. These pumps
include NorA (and others) in S. aureus [196–201]
and PmrA (and others) in pneumococci [202–207].
Also, interrogation of the E. faecalis genome led to
characterisation of emeA, which encodes a NorA
homologue, and to the recognition of many other
putative MDRs in this species [208,209].
A novel ﬂuoroquinolone resistance mechanism,
involving decreased expression of topoisomerase
IV, was recently identiﬁed in a laboratory-gener-
ated S. aureus mutant that showed low-level
ciproﬂoxacin resistance (the MIC rose 4- to 8-fold,
from 0.125–0.25 to 1 mg/L) [210].
OXAZOLIDINONE RESISTANCE
Linezolidwas the ﬁrst oxazolidinone to be licensed
[211], although othermembers of this novel class of
antibacterial agents are in development [3]. Oxa-
zolidinones bind to the 50S ribosomal sub-unit
[212] and prevent protein synthesis by inhibiting
formation of the 70S ribosomal initiation complex.
Cross-linking studies have revealed that linezolid
binds with the conserved nucleotide A2602 in the
23S rRNA, with ribosomal protein L27, and with
ribosome-associated LepA (a protein with homol-
ogy to translation factors), indicating that peptidyl
transferase is the primary target for the agent [213].
The oxazolidinones are synthetic agents and
there is no pre-existing reservoir of resistance.
Resistance arises, not from the acquisition of
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genes, but by mutation in chromosomal genes
encoding 23S rRNA. A number of mutations
affecting the peptidyl transferase domain of the
23S rRNA have been shown to confer linezolid
resistance in laboratory-generated mutants [214].
Mutation of nucleotide G2576 ﬁ T (with refer-
ence to the Escherichia coli numbering of GenBank
AF053964) is the most widely reported mutation
among linezolid-resistant clinical isolates (MIC,
>4 mg/L), having been found in enterococci [215–
218], S. aureus [219–221], and also in single isolates
of S. epidermidis and Streptococcus oralis (the latter
isolates had additional mutations in their 23S
rRNA, but the contribution of these to linezolid
resistance, if any, was not ascertained) [222]; a
T2500A mutation was recently reported in a
clinical isolate of S. aureus [223].
Unusually for bacterial genes, the rDNA genes
of most species are present in multiple copies.
Oxazolidinone resistance probably arises via a
two-step process, an initial mutational event
affecting one gene copy, followed by intra-
genomic recombination (also known as gene
conversion) events to distribute the mutation to
sufﬁcient rDNA alleles to confer phenotypic
resistance. In support of this, the MIC of linezo-
lid for resistant enterococci correlates with the
copy number of rDNA alleles possessing the
mutation [224–226], and resistance arose less
readily in a recombination-deﬁcient strain of
E. faecalis [227].
To date, linezolid resistance has emerged only
rarely and usually during treatment, although
there are exceptions to both of these generalisa-
tions [228,229]. As resistance is mutational and
not transferable between strains, we must be
concerned about the potential for spread of the
linezolid-resistant strains. Thus, infection control
is the major issue when linezolid-resistant entero-
cocci or staphylococci are isolated. A nosocomial
cluster of infections caused by linezolid-resistant
enterococci affecting eight patients on an oncol-
ogy ward in the USA has been reported [230],
but there are no reports of cross-infection with
linezolid-resistant MRSA. However, unfortu-
nately, the prevalence of MRSA in many countries
stands as poor testament to the effectiveness of
infection control in many hospitals. In the UK, the
emergence during therapy of linezolid-resistant
isolates of EMRSA-15 [220] is a worrying devel-
opment given the predilection of this strain for
nosocomial spread [6,7].
RESISTANCE TO OTHER AGENTS
Chloramphenicol
Most resistance to chloramphenicol in Gram-pos-
itive cocci is mediated by chloramphenicol acetyl
transferases, which are encoded by plasmid-medi-
ated or chromosomally integrated cat genes. Many
cat variants have been identiﬁed, and they fall into
distinct classes on the basis of hybridisation data
and their sequence [231]. Several are shared by
staphylococci, enterococci and streptococci. For
example, the staphylococcal catpC194 determinant
[232] is associated with conjugative transposon
Tn1545 in pneumococci [116,233,234]; it is also
found in other streptococci and in enterococci
[231]. The catpC221 and catpSCS7 determinants are
also from staphylococci, but have been detected
in enterococci and streptococci [231,232,235].
Fusidic acid
Resistance to fusidic acid (an inhibitor of elonga-
tion factor G) arises in staphylococci by various
mechanisms. Fusidic acid monotherapy is usually
avoided in hospitals because of the likelihood of
selection of resistant mutants [236]; these usually
have alterations in fusA, which encodes EF-G
[237–240]. In the UK, increased (mainly topical)
use of the agent in the community has been
associated with rising resistance rates in S. aureus
[241]. Other fusidic acid resistance mechanisms
occur in staphylococci, but few have been pre-
cisely deﬁned; they include impermeability and
efﬂux, and some are plasmid-mediated
[239,242,243]. Inactivation of fusidic acid by some
CAT enzymes has also been reported, but the
clinical relevance of this to staphylococci that are
fusidic acid-susceptible, chloramphenicol-resist-
ant in vitro is unknown [239].
Mupirocin
Mupirocin is a topical anti-staphylococcal agent
used, for example, to eradicate MRSA carriage. It
inhibits isoleucyl tRNA synthetase, thereby stop-
ping protein synthesis. Staphylococci can develop
resistance to mupirocin by two mechanisms:
chromosomal mutations in the chromosomal ileS
gene give rise to low levels of resistance (MIC,
8–128 mg/L) [244,245], which are not considered
to be clinically signiﬁcant because topical appli-
cation gives local concentrations far in excess of
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the MIC; acquisition of a second, resistant isoleu-
cyl tRNA synthetase (encoded by mupA, which is
often plasmid-mediated) by-passes the action of
mupirocin and gives clinically signiﬁcant, high-
level resistance (MIC, ‡256 mg/L) [244,246–248].
Rifampicin
Rifampicin resistance arises readily via chromo-
somal mutations in rpoB, which encodes the
b-subunit of RNA polymerase. This mechanism
has been described in staphylococci [249–251],
enterococci [252] and streptococci [253]. Nocardia
and related bacteria are able to inactivate rifampi-
cin via a number of mechanisms [254]. These
mechanisms have not been reported in Gram-
positive cocci, although arr-2 (encoding a rifampi-
cin ADP ribosyltransferase) has been detected as
an integron-borne resistance cassette in Gram-
negative bacteria [255].
Tetracyclines
Tetracycline resistance in Gram-positive cocci is
mediated by two main mechanisms, efﬂux pumps
and ribosomal protection systems [256,257]. Typ-
ically, the efﬂux pumps confer resistance (MIC,
>8 mg/L) to tetracycline and doxycycline, but not
to minocycline, whereas the ribosomal protection
systems confer resistance also to minocycline. The
speciﬁc mechanisms described are: for staphylo-
cocci, the Tet(K) and Tet(L) efﬂux pumps, plus the
Tet(M) and Tet(O) ribosomal protection systems
[256,258]; for enterococci, Tet(K), Tet(L), Tet(M),
Tet(O), plus the Tet(S) ribosomal protection sys-
tem, and the tet(U) deteminant, which confers
resistance by an undeﬁned mechanism [256,259];
for streptococci, Tet(K), Tet(L), Tet(M), Tet(O), plus
the Tet(Q) andTet(T) ribosomal protection systems
[256]. Arguably, tet(M), associated with the conju-
gative transposon Tn916, is one of the most
successful of all antibiotic resistance determinants.
Mechanisms conferring resistance to the gly-
cylcycline tigecycline have not yet been identiﬁed
in Gram-positive cocci. Bacteria resistant to earlier
tetracycline analogues by efﬂux or ribosomal
protection mechanisms usually remain suscept-
ible to tigecycline [3]. However, mutations in the
Tet(A) and Tet(B) efﬂux pumps of Gram-negative
bacteria can confer resistance to tigecycline
[256,260,261], and the AcrAB pump is responsible
for the intrinsic reduced susceptibility of Proteus
mirabilis to tigecycline [262]. By analogy, it seems
possible that efﬂux-mediated reduced suscepti-
bility will eventually emerge in Gram-positives.
Trimethoprim
In pneumococci, resistance to trimethoprim
reﬂects mutations in the chromosomal dfr gene
encoding dihydrofolate reductase (DHFR) [233].
As with the PBP changes that mediate b-lactam
resistance in this species, interspecies recombina-
tion with other streptococci is considered import-
ant for the diversiﬁcation of pneumococcal dfr
[263]. Chromosomal dfr mutations also occur in
staphylococci [264] and enterococci [265].
Plasmid-mediated resistance in staphylococci is
associated with acquired DHFR S1 and S2, enco-
ded by dfrA and dfrD respectively [266,267]. Both
probably represent the ‘escape’ to plasmids of
chromosomal dfr genes from CoNS species.
Transferable, plasmid-mediated trimethoprim
resistance has been observed in enterococci,
although the mechanism was not elucidated
[268]. An acquired, chromosomally located DHFR
(encoded by dfrF), which conferred high-level
trimethoprim resistance (MIC, >1024 mg/L) has
been characterised in a strain of E. faecalis [265].
When sought, the staphylococcal dfrA determin-
ant has not been found in enterococci [269].
CONCLUDING REMARKS
Bacteria have proved themselves able to develop
or acquire resistance to every antibiotic class used
against them. This review has summarised the
myriad mechanisms encountered in Gram-posit-
ive cocci, but the mechanisms of Gram-negative
bacteria are equally diverse and, arguably, pre-
sent far greater clinical challenges at the present
time. Anti-Gram-positive agents such as linezolid
and quinupristin/dalfopristin retain good activity
against the majority of MRSA, GRE and strepto-
cocci, but resistance has been reported even to
these. We need to develop agents with enhanced
modes of action, such as the second-generation
glycopeptide oritavancin or agents with novel
mechanisms of action, such as the lipopeptide
daptomycin [3], while bearing in mind the fact
that any antibiotic has only a limited period of
‘virginity’ before resistance emerges. We must
implement strategies that maximise these periods
and maintain the efﬁcacy of new agents.
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